Positive News SentimentPositive NewsNASDAQ:VTGN VistaGen Therapeutics (VTGN) Stock Price, News & Analysis $0.26 +0.01 (+4.67%) As of 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsNews and TrendsOptions ChainOwnershipSEC Filings About VistaGen Therapeutics Stock (NASDAQ:VTGN) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get VistaGen Therapeutics alerts:Sign Up Key Stats Today's Range$0.24▼$0.2750-Day Range$0.23▼$0.7652-Week Range$0.20▼$5.14Volume562,410 shsAverage Volume7.28 million shsMarket Capitalization$11.54 millionP/E RatioN/ADividend YieldN/APrice Target$0.95Consensus RatingReduce Company Overview VistaGen Therapeutics, Inc. (NASDAQ:VTGN) is a clinical-stage biopharmaceutical company dedicated to the discovery and development of next-generation medicines for central nervous system disorders. Incorporated in Delaware in 1998 and headquartered in South San Francisco, California, VistaGen applies advanced human pluripotent stem cell technologies to accelerate drug candidate validation and optimization. The company’s core focus is on addressing unmet medical needs in major depressive disorder, neuropathic pain and dermatological conditions. The company’s lead candidate, AV-101, is an oral prodrug designed to modulate glutamatergic neurotransmission via the N-methyl-D-aspartate (NMDA) receptor pathway, with clinical programs targeting major depressive disorder and neuropathic pain. VistaGen also develops PH-10, a topical neuroactive small molecule in clinical development for psoriasis and atopic dermatitis. To broaden its development reach, VistaGen has entered strategic partnerships, including a licensing agreement with Yuhan Corporation for AV-101 in South Korea, and continues to advance its clinical and regulatory strategy primarily in North America and Asia. VistaGen’s proprietary Human Clinical Drug Rescue and ReRationalization platform employs patient-derived pluripotent stem cell–derived neural and cardiac cells to predict clinical efficacy and safety, reduce late-stage development risk and complement traditional preclinical models. This platform supports both in-house pipeline programs and collaborative research initiatives. Leading the company is President and Chief Executive Officer Shawn K. Singh, who has overseen VistaGen’s research and corporate development efforts since joining in 2014 and remains committed to translating innovative science into new therapeutic options for underserved patient populations.AI Generated. May Contain Errors. Read More VistaGen Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks53rd Percentile Overall ScoreVTGN MarketRank™: VistaGen Therapeutics scored higher than 53% of companies evaluated by MarketBeat, and ranked 505th out of 918 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.1 / 5Analyst RatingReduce Consensus RatingVistaGen Therapeutics has received a consensus rating of Reduce. The company's average rating score is 1.80, and is based on no strong buy ratings, no buy ratings, 4 hold ratings, and 1 sell rating.Upside PotentialVistaGen Therapeutics has a consensus price target of $0.95, representing about 265.4% upside from its current price of $0.26.Amount of Analyst CoverageVistaGen Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about VistaGen Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for VistaGen Therapeutics are expected to decrease in the coming year, from ($1.32) to ($1.54) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of VistaGen Therapeutics is -0.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of VistaGen Therapeutics is -0.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioVistaGen Therapeutics has a P/B Ratio of 0.47. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about VistaGen Therapeutics' valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted4.53% of the float of VistaGen Therapeutics has been sold short.Short Interest Ratio / Days to CoverVistaGen Therapeutics has a short interest ratio ("days to cover") of 0.15, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in VistaGen Therapeutics has recently decreased by 2.64%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldVistaGen Therapeutics does not currently pay a dividend.Dividend GrowthVistaGen Therapeutics does not have a long track record of dividend growth. News and Social Media3.0 / 5News SentimentN/A News SentimentVistaGen Therapeutics has a news sentiment score of 1.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.87 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 1 news article for VistaGen Therapeutics this week, compared to 5 articles on an average week.Search InterestOnly 2 people have searched for VTGN on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, VistaGen Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders2.93% of the stock of VistaGen Therapeutics is held by insiders.Percentage Held by Institutions78.39% of the stock of VistaGen Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about VistaGen Therapeutics' insider trading history. Receive VTGN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for VistaGen Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. VTGN Stock News HeadlinesVistagen Reports Fiscal Year 2027 First Quarter Financial Results and Corporate UpdateAugust 14, 2026 | globenewswire.comVistagen Announces Topline Results for Repeat Dose Study of Fasedienol for Acute Treatment of Social Anxiety DisorderAugust 6, 2026 | globenewswire.comA “bloodbath” Is ComingReports suggest some Silicon Valley billionaires are stockpiling gold, guns, and gas masks - or leaving the country entirely - as concerns grow about the next phase of the AI market. One AI insider says investors should reassess their positions before August 31, pointing to a critical shift ahead for tech and AI-related stocks.August 26 at 1:00 AM | TradeSmith (Ad)SRX Global (NYSE American: SRXH) Acquires Stake in Vistagen TherapeuticsAugust 4, 2026 | markets.businessinsider.comVistagen Appoints Douglas J. Williamson to its Board of DirectorsJuly 31, 2026 | globenewswire.comStifel Nicolaus Remains a Hold on VistaGen Therapeutics (VTGN)July 18, 2026 | theglobeandmail.comIs Vistagen Therapeutics, Inc. (VTGN) Stock Facing New Challenges After PALISADE-4 Clinical Trial Results?July 15, 2026 | insidermonkey.comVistaGen Therapeutics (VTGN) Receives a Rating Update from a Top AnalystJuly 4, 2026 | theglobeandmail.comSee More Headlines VTGN Stock Analysis - Frequently Asked Questions How have VTGN shares performed this year? VistaGen Therapeutics' stock was trading at $0.6619 at the beginning of 2026. Since then, VTGN shares have decreased by 60.7% and is now trading at $0.26. How were VistaGen Therapeutics' earnings last quarter? VistaGen Therapeutics, Inc. (NASDAQ:VTGN) announced its quarterly earnings results on Friday, August, 14th. The company reported ($0.30) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.37) by $0.07. The company had revenue of $1.48 million for the quarter, compared to analyst estimates of $0.50 million. VistaGen Therapeutics had a negative trailing twelve-month return on equity of 152.59% and a negative net margin of 2,702.64%. When did VistaGen Therapeutics' stock split? VistaGen Therapeutics shares reverse split on Wednesday, June 7th 2023.The 1-30 reverse split was announced on Wednesday, June 7th 2023. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, June 7th 2023. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. Who are VistaGen Therapeutics' major shareholders? Top institutional shareholders of VistaGen Therapeutics include ADAR1 Capital Management LLC (0.79%), BlackRock Inc. (0.78%), BlackRock Inc. (0.58%) and Man Group plc (0.25%). View institutional ownership trends. How do I buy shares of VistaGen Therapeutics? Shares of VTGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of VistaGen Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that VistaGen Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), CrowdStrike (CRWD), Adobe (ADBE), Advanced Micro Devices (AMD) and Arista Networks (ANET). Company Calendar Last Earnings8/14/2026Today8/26/2026AGM 20269/10/2026Next Earnings (Estimated)11/12/2026Fiscal Year End3/31/2027Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (8m+) 1-Year History Aug 25 Nov 25 Feb 26 May 26 Aug 26 VTGN's financial health is in the Red zone, according to TradeSmith. VTGN has been in this zone for over 8 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:VTGN CIK1411685 Webwww.vistagen.com Phone(650) 577-3600Fax888-482-2602Employees40Year Founded1998Price Target and Rating Average Price Target for VistaGen Therapeutics$0.95 High Price Target$1.00 Low Price Target$0.90 Potential Upside/Downside+265.4%Consensus RatingReduce Rating Score (0-4)1.80 Research Coverage5 Analysts Profitability EPS (Trailing Twelve Months)($1.66) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$69.68 million Net Margins-2,702.64% Pretax Margin-2,702.36% Return on Equity-152.59% Return on Assets-117.45% Debt Debt-to-Equity RatioN/A Current Ratio3.07 Quick Ratio3.07 Sales & Book Value Annual Sales$2.50 million Price / Sales4.61 Cash FlowN/A Price / Cash FlowN/A Book Value$0.55 per share Price / Book0.47Miscellaneous Outstanding Shares44,377,000Free Float43,077,000Market Cap$11.54 million OptionableOptionable Beta0.41 Social Links Options Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free Report This page (NASDAQ:VTGN) was last updated on 8/26/2026 by MarketBeat.com Staff. From Our PartnersA $382 trillion migration and the position no one is talking aboutTrump just signed a law requiring America's entire $382 trillion financial system to migrate to a new money ne...Awesomely | SponsoredMILLIONAIRE MASTERCLASS INVITE: AltucherJames Altucher says Elon Musk is preparing an unprecedented project set to surface on September 25. Altuche...Paradigm Press | SponsoredChina is not hedging. It's escaping.China's US Treasury holdings have fallen from a peak of $1.32 trillion to roughly $659 billion, an 18-year low...Behind the Markets | SponsoredYour withdrawal order could cost you in taxesIf you have $2M or more saved, the 4% rule points to roughly $92,000 a year - but it's a single-variable answe...SmartAsset | SponsoredThe trade I’ve been waiting for since 2011Ross Givens, Director of Research at Traders Agency, is calling for gold to reach $10,000 an ounce this superc...Traders Agency | SponsoredYour book attachedYour Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...Profits Run | SponsoredJeff Brown and Marc Chaikin's latest AI prediction explainedJeff Brown and Marc Chaikin - the duo who identified Nvidia a decade ago - are forecasting that Elon Musk's AI...Brownstone Research | SponsoredBuy this stock todayMost tech companies skip dividends entirely. This one doesn't, paying shareholders like clockwork while flying...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding VistaGen Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share VistaGen Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
